{
    "info": {
        "nct_id": "NCT04660760",
        "official_title": "Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study",
        "inclusion_criteria": "* Age >= 18 years\n* Histological or cytological confirmation of adenocarcinoma of the stomach or gastroesophageal junction\n* Have locally advanced unresectable or metastatic disease that has progressed =< 180 days since last treatment\n* One or more measurable or nonmeasurable evaluable lesions per Response Evaluation Criteria in Solid Tumors (RECIST)\n* Planned for second line treatment defined by failing or were intolerant to previous standard chemotherapies containing one or more of the following agents:\n\n  * Fluoropyrimidine (IV 5-FU or capecitabine) and platinum (cisplatin or oxaliplatin)\n  * Trastuzumab in case of HER2-positive disease\n  * NOTE: For the patients whose disease recurred =< 168 days from the last dose of adjuvant anticancer chemotherapy, that adjuvant anticancer chemotherapy is counted as 1 prior chemotherapy line\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Ability to swallow oral medications\n* Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 7 days prior to registration)\n* Platelet count >= 100,000/mm^3 (obtained =< 7 days prior to registration)\n* Hemoglobin >= 9.0 g/dL (obtained =< 7 days prior to registration)\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)\n* Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN ( =< 5.0 x UNL, if with liver metastasis) (obtained =< 7 days prior to registration)\n* International normalized ratio (INR) =< 1.5 x ULN, and a partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy) (obtained =< 7 days prior to registration)\n\n  * Note: Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy\n  * Note: Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH)\n  * Exception: If receiving warfarin, the patient must have an INR =< 3.0. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)\n* Urinary protein is =< 1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for protein must demonstrate =< 1000 mg of protein in 24 hours to allow participation in this protocol) (obtained =< 7 days prior to registration)\n* Creatinine =< 1.5 times the ULN or creatinine clearance (measured via 24-hour urine collection) >= 50 mL/minute (that is, if serum creatinine is >= 1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) (obtained =< 7 days prior to registration)\n* Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Provide informed written consent =< 28 days prior to registration\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n* Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant women\n  * Nursing women\n  * Women of childbearing potential who are unwilling to employ adequate contraception\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Previous treatment with TAS-102 or ramucirumab\n* Previous taxane therapy =< 180 days prior to registration\n* Any grade 3-4 gastrointestinal (GI) bleeding =< 90 days prior to registration\n* History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \"significant\") =< 90 days prior to registration\n* Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, =< 180 days prior to registration\n* Prior history of GI perforation/fistula =< 180 days of registration or risk factors for perforation\n* Serious or nonhealing wound, ulcer, or bone fracture =< 28 days prior to registration\n* Major surgery =< 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement =< 7 days prior to registration\n* Elective or planned major surgery to be performed during the course of the clinical trial\n* Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. NOTE: Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis\n* Uncontrolled or poorly-controlled hypertension (>= 150 mmHg systolic or >= 90 mmHg diastolic for >= 4 weeks) despite standard medical management\n* Immunocompromised and known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Other active malignancy =< 3 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer\n* Receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. NOTE: Once-daily aspirin use (maximum dose 325 mg/day) is permitted",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histological or cytological confirmation of adenocarcinoma of the stomach or gastroesophageal junction",
            "criterions": [
                {
                    "exact_snippets": "Histological or cytological confirmation",
                    "criterion": "adenocarcinoma diagnosis method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "adenocarcinoma of the stomach or gastroesophageal junction",
                    "criterion": "adenocarcinoma location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "stomach",
                                "gastroesophageal junction"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)",
            "criterions": [
                {
                    "exact_snippets": "Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)",
                    "criterion": "willingness to return for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "Active Monitoring Phase"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to swallow oral medications",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)",
            "criterions": [
                {
                    "exact_snippets": "the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)",
                    "criterion": "reproductive status or contraception use",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "postmenopausal",
                                "surgically sterile"
                            ]
                        },
                        {
                            "requirement_type": "contraception use",
                            "expected_value": "using effective contraception (hormonal or barrier methods)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "ANC laboratory value timing",
                    "requirements": [
                        {
                            "requirement_type": "time from registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: For the patients whose disease recurred =< 168 days from the last dose of adjuvant anticancer chemotherapy, that adjuvant anticancer chemotherapy is counted as 1 prior chemotherapy line",
            "criterions": [
                {
                    "exact_snippets": "disease recurred =< 168 days from the last dose of adjuvant anticancer chemotherapy",
                    "criterion": "time to disease recurrence after last adjuvant anticancer chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 168,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adjuvant anticancer chemotherapy is counted as 1 prior chemotherapy line",
                    "criterion": "counting of adjuvant anticancer chemotherapy as prior chemotherapy line",
                    "requirements": [
                        {
                            "requirement_type": "counting rule",
                            "expected_value": "adjuvant anticancer chemotherapy is counted as 1 prior chemotherapy line if disease recurred <= 168 days from last dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9.0 g/dL (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "hemoglobin measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Trastuzumab in case of HER2-positive disease",
            "criterions": [
                {
                    "exact_snippets": "Trastuzumab in case of HER2-positive disease",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fluoropyrimidine (IV 5-FU or capecitabine) and platinum (cisplatin or oxaliplatin)",
            "criterions": [
                {
                    "exact_snippets": "Fluoropyrimidine (IV 5-FU or capecitabine)",
                    "criterion": "fluoropyrimidine chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "IV 5-FU",
                                "capecitabine"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "platinum (cisplatin or oxaliplatin)",
                    "criterion": "platinum chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "cisplatin",
                                "oxaliplatin"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "total bilirubin measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* One or more measurable or nonmeasurable evaluable lesions per Response Evaluation Criteria in Solid Tumors (RECIST)",
            "criterions": [
                {
                    "exact_snippets": "One or more measurable or nonmeasurable evaluable lesions per Response Evaluation Criteria in Solid Tumors (RECIST)",
                    "criterion": "evaluable lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "nonmeasurable"
                            ]
                        },
                        {
                            "requirement_type": "evaluation_standard",
                            "expected_value": "Response Evaluation Criteria in Solid Tumors (RECIST)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test ... =< 7 days prior to registration ... for women of childbearing potential only",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to registration"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of childbearing potential only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have locally advanced unresectable or metastatic disease that has progressed =< 180 days since last treatment",
            "criterions": [
                {
                    "exact_snippets": "locally advanced unresectable or metastatic disease",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "disease that has progressed =< 180 days since last treatment",
                    "criterion": "disease progression since last treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression_time_since_last_treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned for second line treatment defined by failing or were intolerant to previous standard chemotherapies containing one or more of the following agents:",
            "criterions": [
                {
                    "exact_snippets": "Planned for second line treatment",
                    "criterion": "treatment line",
                    "requirements": [
                        {
                            "requirement_type": "planned line of treatment",
                            "expected_value": ">=2"
                        }
                    ]
                },
                {
                    "exact_snippets": "failing or were intolerant to previous standard chemotherapies",
                    "criterion": "response to previous standard chemotherapies",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "failure",
                                "intolerance"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "previous standard chemotherapies containing one or more of the following agents",
                    "criterion": "previous chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "contains specific agents",
                            "expected_value": "one or more of the following agents"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exception: If receiving warfarin, the patient must have an INR =< 3.0. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)",
            "criterions": [
                {
                    "exact_snippets": "If receiving warfarin, the patient must have an INR =< 3.0",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy)",
                    "criterion": "active bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no bleeding within 14 days prior to first dose of protocol therapy",
                    "criterion": "bleeding within 14 days prior to first dose of protocol therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no ... pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)",
                    "criterion": "pathological condition with high risk of bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) =< 1.5 x ULN, and a partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy) (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) =< 1.5 x ULN",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) =< 5 seconds above the ULN",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "seconds above the ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless receiving anticoagulation therapy",
                    "criterion": "anticoagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH)",
            "criterions": [
                {
                    "exact_snippets": "Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH)",
                    "criterion": "anticoagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": "full-dose"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "oral anticoagulant",
                                "low molecular weight heparin (LMWH)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine =< 1.5 times the ULN or creatinine clearance (measured via 24-hour urine collection) >= 50 mL/minute (that is, if serum creatinine is >= 1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine =< 1.5 times the ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times the ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance (measured via 24-hour urine collection) >= 50 mL/minute",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/minute"
                            }
                        },
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "measured via 24-hour urine collection"
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "laboratory value timing",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to complete questionnaire(s) by themselves or with assistance",
            "criterions": [
                {
                    "exact_snippets": "Ability to complete questionnaire(s) by themselves or with assistance",
                    "criterion": "ability to complete questionnaires",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provide informed written consent =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Provide informed written consent =< 28 days prior to registration",
                    "criterion": "informed written consent",
                    "requirements": [
                        {
                            "requirement_type": "provision timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving warfarin must be switched to low molecular weight heparin",
                    "criterion": "anticoagulant medication",
                    "requirements": [
                        {
                            "requirement_type": "current medication",
                            "expected_value": "low molecular weight heparin"
                        }
                    ]
                },
                {
                    "exact_snippets": "have achieved stable coagulation profile prior to first dose of protocol therapy",
                    "criterion": "coagulation profile",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN ( =< 5.0 x UNL, if with liver metastasis) (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate transaminase (AST) ... =< 3 x ULN ( =< 5.0 x UNL, if with liver metastasis) (obtained =< 7 days prior to registration)",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if with liver metastasis)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "timing of measurement",
                            "expected_value": "obtained =< 7 days prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (ALT) ... =< 3 x ULN ( =< 5.0 x UNL, if with liver metastasis) (obtained =< 7 days prior to registration)",
                    "criterion": "alanine transaminase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if with liver metastasis)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "timing of measurement",
                            "expected_value": "obtained =< 7 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000/mm^3 (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "platelet count measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urinary protein is =< 1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for protein must demonstrate =< 1000 mg of protein in 24 hours to allow participation in this protocol) (obtained =< 7 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Urinary protein is =< 1+ on dipstick or routine urinalysis (UA",
                    "criterion": "urinary protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "test_method",
                            "expected_value": [
                                "dipstick",
                                "routine urinalysis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for protein must demonstrate =< 1000 mg of protein in 24 hours",
                    "criterion": "urinary protein (24-hour collection)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1000,
                                "unit": "mg/24 hours"
                            }
                        },
                        {
                            "requirement_type": "test_method",
                            "expected_value": "24-hour urine collection"
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to registration",
                    "criterion": "timing of urinary protein test",
                    "requirements": [
                        {
                            "requirement_type": "time from registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Pregnant women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, =< 180 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, =< 180 days prior to registration",
                    "criterion": "arterial thromboembolic events",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to registration"
                            }
                        },
                        {
                            "requirement_type": "event_types",
                            "expected_value": [
                                "myocardial infarction",
                                "transient ischemic attack",
                                "cerebrovascular accident",
                                "unstable angina"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
            "criterions": [
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator judgment of appropriateness for study entry",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which ... would ... interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "interference with assessment of safety and toxicity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious or nonhealing wound, ulcer, or bone fracture =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Serious or nonhealing wound, ulcer, or bone fracture =< 28 days prior to registration",
                    "criterion": "serious or nonhealing wound, ulcer, or bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "presence within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other active malignancy =< 3 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy =< 3 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years prior to registration"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "non-melanotic skin cancer",
                                "carcinoma-in-situ of the cervix"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer",
                    "criterion": "prior malignancy treatment",
                    "requirements": [
                        {
                            "requirement_type": "receiving other specific treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential who are unwilling to employ adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to employ adequate contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "adequacy of contraception",
                            "expected_value": "adequate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous taxane therapy =< 180 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Previous taxane therapy =< 180 days prior to registration",
                    "criterion": "previous taxane therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery =< 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement =< 7 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Major surgery =< 28 days prior to first dose of protocol therapy",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "minor surgery/subcutaneous venous access device placement =< 7 days prior to registration",
                    "criterion": "minor surgery or subcutaneous venous access device placement",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled or poorly-controlled hypertension (>= 150 mmHg systolic or >= 90 mmHg diastolic for >= 4 weeks) despite standard medical management",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled or poorly-controlled hypertension (>= 150 mmHg systolic or >= 90 mmHg diastolic for >= 4 weeks) despite standard medical management",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": [
                                "uncontrolled",
                                "poorly-controlled"
                            ]
                        },
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "treatment_response",
                            "expected_value": "despite standard medical management"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunocompromised and known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy",
            "criterions": [
                {
                    "exact_snippets": "Immunocompromised",
                    "criterion": "immunocompromised status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known to be human immunodeficiency virus (HIV) positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "HIV positive",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "currently receiving antiretroviral therapy",
                    "criterion": "antiretroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any grade 3-4 gastrointestinal (GI) bleeding =< 90 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Any grade 3-4 gastrointestinal (GI) bleeding =< 90 days prior to registration",
                    "criterion": "gastrointestinal (GI) bleeding",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Elective or planned major surgery to be performed during the course of the clinical trial",
            "criterions": [
                {
                    "exact_snippets": "Elective or planned major surgery to be performed during the course of the clinical trial",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned during trial",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of GI perforation/fistula =< 180 days of registration or risk factors for perforation",
            "criterions": [
                {
                    "exact_snippets": "Prior history of GI perforation/fistula =< 180 days of registration",
                    "criterion": "history of GI perforation/fistula",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "risk factors for perforation",
                    "criterion": "risk factors for perforation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. NOTE: Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis",
            "criterions": [
                {
                    "exact_snippets": "Cirrhosis at a level of Child-Pugh B (or worse)",
                    "criterion": "cirrhosis severity (Child-Pugh score)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "Child-Pugh score (B or worse)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis (any degree) and a history of hepatic encephalopathy",
                    "criterion": "hepatic encephalopathy history",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis (any degree) and ... clinically meaningful ascites resulting from cirrhosis",
                    "criterion": "clinically meaningful ascites due to cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis",
                    "criterion": "ascites management",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "diuretics",
                                "paracentesis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm",
            "criterions": [
                {
                    "exact_snippets": "Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm",
                    "criterion": "receipt of other investigational agent for primary neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with TAS-102 or ramucirumab",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with TAS-102",
                    "criterion": "previous treatment with TAS-102",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous treatment with ... ramucirumab",
                    "criterion": "previous treatment with ramucirumab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial",
            "criterions": [
                {
                    "exact_snippets": "Patients known to be HIV positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without clinical evidence of an immunocompromised state",
                    "criterion": "immunocompromised state",
                    "requirements": [
                        {
                            "requirement_type": "clinical evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",
            "criterions": [
                {
                    "exact_snippets": "this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown",
                    "criterion": "investigational agent with unknown genotoxic, mutagenic, and teratogenic effects",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing or active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ... symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ... unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ... cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ... psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "limits compliance with study requirements",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. NOTE: Once-daily aspirin use (maximum dose 325 mg/day) is permitted",
            "criterions": [
                {
                    "exact_snippets": "Receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents.",
                    "criterion": "chronic antiplatelet therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Once-daily aspirin use (maximum dose 325 mg/day) is permitted",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": "once-daily"
                        },
                        {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \"significant\") =< 90 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "History of deep vein thrombosis (DVT) ... =< 90 days prior to registration",
                    "criterion": "deep vein thrombosis (DVT)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of pulmonary embolism (PE) ... =< 90 days prior to registration",
                    "criterion": "pulmonary embolism (PE)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... any other significant thromboembolism ... =< 90 days prior to registration",
                    "criterion": "significant thromboembolism (excluding venous port or catheter thrombosis or superficial venous thrombosis)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}